Thallion Pharmaceuticals Inc. (TSX:TLN) announced it has conventional leave from the
Therapeutic stock Directorate of Health Canada to initiate a Phase II clinical trial evaluating
TLN-232 as a regimen for metastatic melanoma in next that have failed ...
(more)Little more than one in eight phase II cancer subjective trials with beneficient results go
forward to the larger, phase III stage that's needed to bring a new therapy to patients, a new
study finds.
...
(more)Eldavojohn writes "Perhaps unsatisfied with the closeups that Google Moon has to offer, China
has decided to survey the moon down to the 'inch'. In the second half of 2007, they plan to
launch an unmanned lunar satellite to first orbit the moon, land ...
(more)